Bone Biologics (BBLG) Change in Account Payables (2014)
Bone Biologics (BBLG) reported Change in Account Payables of -$140175.0 for Q4 2014, down 1575.37% quarter-over-quarter from $9501.0 in Q3 2014.
Bone Biologics (BBLG) Change in Account Payables (2014) Analysis & Trends
Bone Biologics (BBLG) has 1 years of Change in Account Payables data on file, last reported at -$140175.0 in Q4 2014.
- Change in Account Payables for Q4 2014 came in at -$140175.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2014 was -$41300.0 (changed N/A YoY), and the FY2014 annual result was -$41300.0, down 200.0% from the prior year.
- Change in Account Payables eased to -$140175.0 in Q4 2014 per BBLG's latest filing, from $9501.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $89441.0 in Q1 2014 and troughed at -$140175.0 in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -9.42 Mn |
| 10 | Bone Biologics | 1.47 Mn | 1.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | -140,175.00 |
| Dec 31, 2014 | -140,175.00 |
| Sep 30, 2014 | 9,501.00 |
| Sep 30, 2014 | 9,501.00 |
| Jun 30, 2014 | -67.00 |
| Jun 30, 2014 | -67.00 |
| Mar 31, 2014 | 89,441.00 |
| Mar 31, 2014 | 89,441.00 |